FIELD: pharmaceutics.
SUBSTANCE: invention relates to a compound of general formula (I), where R1', R1–R9, A, n, m are defined in the claim, its racemate as a p38/MK2 inhibitor capable of inhibiting production of cytokine TNFα, and used for treating diseases, such as arthritis.
EFFECT: disclosed is a terpyridine-diketone compound or a salt thereof, a method for production thereof and use thereof.
11 cl, 6 dwg, 14 tbl, 52 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHENICOL ANTIBACTERIAL AGENTS | 2013 |
|
RU2593204C2 |
| TRIAZOLO-PYRIMIDINE COMPOUNDS AND THEIR USE | 2019 |
|
RU2802866C2 |
| PDE9 INHIBITOR AND ITS USE | 2018 |
|
RU2793732C2 |
| PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATORY AGENTS | 2009 |
|
RU2494099C2 |
| SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND USING THEM | 2010 |
|
RU2553263C2 |
| TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNELS INHIBITOR | 2013 |
|
RU2645158C2 |
| TRICYCLIC NITROGEN-CONTAINING DERIVATIVES OF IMIDAZO[4,5-C]PYRIDINE, HAVING INHIBITING ACTIVITY IN RESPONSE TO HYSTAMINE 4 RECEPTOR (HH4R) | 2012 |
|
RU2628074C2 |
| MORPHOLINO-SUBSTITUTED DERIVATIVES OF BICYCLIC PYRIMIDINE UREA OR CARBAMATE AS MTOR INHIBITORS | 2012 |
|
RU2609208C2 |
| BICYCLIC LACTAMS AND METHODS OF USE THEREOF | 2016 |
|
RU2827714C1 |
| 2,6-SUBSTUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | 2005 |
|
RU2417990C2 |
